Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKER NASDAQ:BMRA NASDAQ:CDIO NASDAQ:VRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKERAkers Biosciences$0.09-7.6%$3.56$1.65▼$6.97$1.46M0.3769,876 shs40.31 million shsBMRABiomerica$3.47+1.9%$3.29$1.93▼$10.16$8.84M0.35284,523 shs15,733 shsCDIOCardio Diagnostics$4.42+2.8%$4.14$3.22▼$53.10$7.69M2.9697,288 shs26,833 shsVRAXVirax Biolabs Group$1.07+11.2%$0.93$0.74▼$9.00$4.58M1.651.73 million shs23,789 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKERAkers Biosciences0.00%-19.72%-37.41%-52.24%-95.13%BMRABiomerica0.00%+7.94%+7.59%-7.61%+27.78%CDIOCardio Diagnostics0.00%+3.61%+15.90%-61.26%-71.90%VRAXVirax Biolabs Group0.00%+6.73%+19.63%+5.20%-17.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKERAkers BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ABMRABiomerica0.6341 of 5 stars0.05.00.00.01.10.80.0CDIOCardio Diagnostics3.2095 of 5 stars3.55.00.00.00.01.70.6VRAXVirax Biolabs Group2.5215 of 5 stars3.53.00.00.01.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKERAkers Biosciences 0.00N/AN/AN/ABMRABiomerica 0.00N/AN/AN/ACDIOCardio Diagnostics 3.00Buy$60.001,257.47% UpsideVRAXVirax Biolabs Group 3.00Buy$3.00180.90% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKERAkers Biosciences$1.58M0.92N/AN/A$5.38 per share0.02BMRABiomerica$5.41M1.63N/AN/A$3.13 per share1.11CDIOCardio Diagnostics$40K192.27N/AN/A$7.10 per share0.62VRAXVirax Biolabs Group$10K463.51N/AN/A$1.26 per share0.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKERAkers Biosciences-$3.89MN/A0.00∞N/AN/A-87.42%-73.31%N/ABMRABiomerica-$5.98M-$2.32N/A∞N/A-85.42%-85.90%-61.06%8/26/2025 (Estimated)CDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-28,539.39%-84.55%-74.63%8/11/2025 (Estimated)VRAXVirax Biolabs Group-$6.06MN/A0.00∞N/AN/AN/AN/AN/ALatest AKER, BMRA, CDIO, and VRAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025N/ACDIOCardio Diagnostics-$1.80N/AN/AN/A$0.08 millionN/A5/15/2025Q1 2025CDIOCardio Diagnostics-$0.06-$0.97-$0.91-$0.97$0.05 million$0.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKERAkers BiosciencesN/AN/AN/AN/AN/ABMRABiomericaN/AN/AN/AN/AN/ACDIOCardio DiagnosticsN/AN/AN/AN/AN/AVRAXVirax Biolabs GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKERAkers BiosciencesN/A9.229.22BMRABiomericaN/A3.762.76CDIOCardio DiagnosticsN/A19.4719.47VRAXVirax Biolabs GroupN/A7.277.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKERAkers Biosciences5.52%BMRABiomerica22.28%CDIOCardio Diagnostics8.06%VRAXVirax Biolabs Group8.61%Insider OwnershipCompanyInsider OwnershipAKERAkers Biosciences0.29%BMRABiomerica15.00%CDIOCardio Diagnostics22.30%VRAXVirax Biolabs Group45.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKERAkers Biosciences416.65 millionN/ANot OptionableBMRABiomerica602.55 million2.16 millionOptionableCDIOCardio Diagnostics11.74 million1.35 millionNot OptionableVRAXVirax Biolabs Group54.34 million2.38 millionNot OptionableAKER, BMRA, CDIO, and VRAX HeadlinesRecent News About These CompaniesVirax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyJuly 20 at 7:31 PM | finanznachrichten.deVirax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price DeficiencyJuly 18 at 4:15 PM | prnewswire.comHC Wainwright & Co. Initiates Coverage of Virax Biolabs Group (VRAX) with Buy RecommendationMarch 31, 2025 | msn.comVirax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy RatingMarch 31, 2025 | benzinga.comVirax Biolabs Launches Clinical Study on T Cell DysfunctionMarch 18, 2025 | msn.comVirax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection SyndromesMarch 18, 2025 | prnewswire.comVirax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation MeetingMarch 13, 2025 | prnewswire.comVirax Biolabs to Present at 19th World Immune Regulation MeetingMarch 5, 2025 | prnewswire.comVirax Biolabs Aligns with US Health Department on Vaccine TransparencyFebruary 25, 2025 | tipranks.comVirax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine EfficacyFebruary 25, 2025 | prnewswire.comCosmos Health expands distribution of Avian Influenza kitsJanuary 23, 2025 | msn.comCosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and KuwaitJanuary 23, 2025 | accessnewswire.comACosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC CountriesJanuary 13, 2025 | accesswire.comAVirax Biolabs Group Ltd (VRAX) Stock: Beyond the Surface of Its Performance?December 19, 2024 | bovnews.comBVirax Biolabs Announces Strategic Goals and Developments for 2025December 18, 2024 | markets.businessinsider.comVirax Biolabs' CEO James Foster Issues Letter to ShareholdersDecember 17, 2024 | prnewswire.comVirax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and SwitzerlandDecember 10, 2024 | prnewswire.comVirax Biolabs Sees Asset Growth Amid Financial LossNovember 22, 2024 | markets.businessinsider.comVirax Biolabs announces distribution agreement with Europa BiositeOctober 23, 2024 | markets.businessinsider.comVirax Biolabs Expands Reach with Europa Biosite DealOctober 23, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseAI Chip Arms Race: 3 Must-Watch Equipment StocksBy Chris Markoch | July 10, 2025View AI Chip Arms Race: 3 Must-Watch Equipment Stocks3 Stocks Offering Diversification in Trump’s Tariff & Trade ResetBy Chris Markoch | July 21, 2025View 3 Stocks Offering Diversification in Trump’s Tariff & Trade ResetAKER, BMRA, CDIO, and VRAX Company DescriptionsAkers Biosciences NASDAQ:AKERAkers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.Biomerica NASDAQ:BMRA$3.46 +0.07 (+1.91%) As of 10:36 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Cardio Diagnostics NASDAQ:CDIO$4.42 +0.12 (+2.79%) As of 10:35 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Virax Biolabs Group NASDAQ:VRAX$1.07 +0.11 (+11.18%) As of 10:37 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
